Company History

February 2019

Acquired RNA-loaded dendritic cell platform technology and assets of Argos Therapeutics

February 2019

February 2019

coIMMUNE incorporated in Delaware

February 2019

April 2020

Acquired CAR-CIK platform technology through acquisition of Formula Pharmaceuticals

April 2020

July 2020

Initiated Phase 2b coIMMUNE-sponsored RNA-loaded DC trial for RCC (CMN-001)

July 2020

October 2020

Completed $45M Series A financing

October 2020

December 2020

Completed investigator-initiated Phase 1/2a CAR-CIK trial for ALL (CMN-005)

December 2020

October 2021

Partnership with cancer center for CAR-CIK in solid tumors

October 2021

2H 2021

Seeking cross-over financing

2H 2021

2H 2021

Started investigator-initiated repeat dosing trial with CMN-005 in ALL

2H 2021

2H 2021

Start investigator-initiated CMN-005 NHL trial

2H 2021